

# GASTRIC CANCER – BIG PUBLIC HEALTH PROBLEM

- 1 million new cases every year
- 3<sup>rd</sup> most common cause of cancer death
- Median survival less than one year
- Chemotherapy is the mainstay treatment


*GREAT UNMET MEDICAL NEED TO  
DEVELOP NEW NOVEL COMPOUNDS*



Professor, GI oncologist  
University of Glasgow  
Ascelia Pharma  
Scientific Advisory Board

# NEED TO DEVELOP NOVEL THERAPIES

- Need to develop novel therapies
- Patients are increasingly referred beyond one and two cycles of chemotherapy
- Rising unmet need for third-line therapy
- Oral combination chemotherapy would be advantageous



# ONCORAL SCIENTIFIC ADVISORY BOARD

## **Prof Josep Taberero, MD, PhD**

Head of the Medical Oncology Department at the Vall d'Hebron Barcelona Hospital Campus, Director of the Vall d'Hebron Institute of Oncology (VHIO), and Professor of Medicine

President (2018 – 2019) of ESMO and an Executive Board and Council Member



## **Prof Jaffer A Ajani, MD**

Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA


Chairs the NCCN committee for gastroesophageal cancers



## **Prof Eric Van Cutsem, MD, PhD**

Professor and Division Head of Digestive Oncology at University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium

Co-founded ESMO GI/World Congress on GI Cancer. Serves/served on the board/committee of ESMO, ASCO, ENET, EORTC, ECCO, ESDO



## **Prof Jeff Evans, MD**

Professor of Translational Cancer Research and Clinical Lead of the Institute of Cancer Sciences, University of Glasgow

Member of the NCRN Upper GI Cancer Pancreatic Cancer and Gastro-Oesophageal Cancer sub-groups

